Compare Definium Therapeutics Inc. Common Shares (DFTX) vs Impinj Inc (PI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Definium Therapeutics Inc. Common Shares vs Impinj Inc — how do they compare? Definium Therapeutics Inc. Common Shares trades at $34.01 (market cap $4.71B), while Impinj Inc trades at $183.12 (market cap $5.84B). The key difference: Impinj Inc is the larger of the two by market cap, and Impinj Inc is more actively traded (14,433 versus 1,966,636). Which is the better fit depends on your goals — on Pluang, investors hold Definium Therapeutics Inc. Common Shares for 0 Days and Impinj Inc for 22 Days on average.
| DFTX | PI | |
|---|---|---|
Market Cap | $4.71B | $5.84B |
Volume | 1,966,636 | 14,433 |
Sector | Health | Technology |
52-Week High | $48.45 | $241.91 |
52-Week Low | $10.68 | $91.34 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $3.67B | $5.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Impinj (PI) trades at $191.04, up 3.81% today, showing strong momentum with a bullish technical signal from moving averages. The stock has beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.86 exceeding expectations. However, the company remains unprofitable with a net income margin of -7.26% for 2026. Analyst consensus is strongly positive with 16 buy ratings and a $178.83 price target, though the current price exceeds this target. Recent news highlights the CFO's stock sale and participation in industry conferences.
The outlook for PI is mixed; strong revenue growth and bullish analyst sentiment support upside, but profitability challenges and high valuation ratios pose risks. Investment opportunity lies in the company's positioning in RFID technology, while key risks include sustained losses and competitive pressures. The stock's proximity to resistance at $192 suggests near-term volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Definium Therapeutics Inc. Common Shares
Definium Therapeutics develops investigational treatments for psychiatric and neurological disorders. Formerly MindMed, it focuses on clinical-stage therapies based on novel psychoactive compounds.
Read more on DFTX →About Impinj Inc
Impinj, Inc. is a leading provider of RAIN RFID (radio-frequency identification) solutions. The company's platform includes endpoints (tag chips), connectivity devices (readers and gateways), and software, enabling businesses to wirelessly identify, locate, and authenticate everyday items. Impinj's technology is crucial for applications in retail, supply chain management, healthcare, and logistics, helping businesses to automate inventory, track assets, and improve operational efficiency.
Read more on PI →
